- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03981289
Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD) (GRASP-01-001)
GRASP-LGMD: Defining Clinical Endpoints in LGMD
Study Overview
Status
Detailed Description
The genetic heterogeneity has been a barrier to broad natural history efforts, with prior investigations often limited to single gene mutations. Much attention is paid to the variability within individual mutations (e.g. distal presentations), as opposed to defining the best strategy for measuring change in overall LGMD disease burden. This presents a major dilemma for LGMD rare disease research: how to balance diverse genes leading to overlapping phenotypes, versus variants in the same gene leading to divergent phenotypes. What is clear, is as a group, LGMDs are chronic and progressive leading to significant lifetime morbidity and represent a large unmet clinical need.
Recent developments in the investigator's genetic understanding of LGMD and molecular approaches to therapy have led to proposed gene replacement therapies for at least three of the LGMD mutations. Several of these gene replacement therapies are currently in pre-clinical/phase 1 testing, leading to an urgent need for natural history data. In addition, non-specific therapies which target muscle mass or function are being tested in other muscular dystrophies and may prove beneficial for LGMD.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jennifer Raymond
- Phone Number: 804-828-6318
- Email: jennifer.raymond@vcuhealth.org
Study Contact Backup
- Name: Ruby Langeslay
- Phone Number: 804-828-8481
- Email: Ruby.langeslay@vcuhealth.org
Study Locations
-
-
-
Newcastle, United Kingdom
- Recruiting
- Newcastle University
-
Contact:
- Nicola McLarty
- Email: nicola.mclarty1@nhs.net
-
Contact:
- Dana Gergely
- Email: dana.gergely@newcastle.ac.uk
-
Principal Investigator:
- Jordi Diaz-Manera, MD
-
Newcastle Upon Tyne, United Kingdom
- Recruiting
- John Walton Muscular Dystrophy Research Centre (Newcastle upon Tyne)
-
Principal Investigator:
- Jordi Diaz-Manera, MD
-
Contact:
- Georgina Boyle
- Phone Number: 0191 241 8652
- Email: Georgina.Boyle@newcastle.ac.uk
-
-
-
-
California
-
Irvine, California, United States, 92697
- Recruiting
- University of California Irvine
-
Principal Investigator:
- Tahseen Mozaffar, MD
-
Contact:
- Lauren Harris
- Phone Number: 714-509-2661
- Email: lnharri1@hs.uci.edu
-
Contact:
- Isela Hernandez
- Phone Number: 714-509-2664
- Email: iselah@hs.uci.edu
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- The University of Colorado Anschutz Medical Campus
-
Principal Investigator:
- Stacy Dixon, MD
-
Contact:
- Alyssa Avilez
- Email: alyssa.avilez@cuanschutz.edu
-
Contact:
- Brianna Blume
- Phone Number: 303-724-6386
- Email: brianna.blume@cuanschutz.edu
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa
-
Principal Investigator:
- Kathryn Mathews, MD
-
Contact:
- Carrie Stephan
- Phone Number: 319-356-2673
- Email: carrie-stephan@uiowa.edu
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Recruiting
- Kansas University Medical Center
-
Contact:
- Kaylene Whited
- Phone Number: 913-574-0009
- Email: kwhited2@kumc.edu
-
Principal Investigator:
- Jeffrey Statland, MD
-
Contact:
- Rebecca Clay
- Phone Number: 913-945-9936
- Email: rclay@kumc.edu
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Recruiting
- Kennedy Krieger Institute
-
Principal Investigator:
- Doris Leung, MD
-
Contact:
- Genila Bibat
- Phone Number: 443-923-2697
- Email: bibat@kennedykrieger.org
-
Contact:
- Georgina DSanson
- Email: Dsanson@kennedykrieger.org
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota
-
Contact:
- Allison Johnston
- Email: joh21779@umn.edu
-
Contact:
- John Martone
- Email: marto045@umn.edu
-
Principal Investigator:
- Peter B Kang, MD
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Principal Investigator:
- Conrad Weihl, MD
-
Contact:
- Michelle Seiffert
- Phone Number: 314-273-7946
- Email: mseiffert@wustl.edu
-
Contact:
- Stephanie Hunn
- Email: spoelker@wustl.edu
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Recruiting
- Nationwide Children's Hospital
-
Principal Investigator:
- Linda Lowes
-
Contact:
- Audrey Beale
- Phone Number: 614-355-6872
- Email: Audrey.Beale@NationwideChildrens.org
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Recruiting
- Virginia Commonwealth University
-
Principal Investigator:
- Nicholas Johnson, MD
-
Contact:
- Anarosa Rezeq
- Email: anarosa.rezeq@vcuhealth.org
-
Contact:
- Shaquila Jolly
- Email: shaquila.jolly@vcuhealth.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria - Arm 1:
- Age between 4-65 at enrollment
- Clinically affected (defined as weakness on bedside evaluation in either a limb-girdle pattern, or in a distal extremity)
- A genetically or functionally confirmed mutation in ANO5, CAPN3, DYSF, DNAJB6 or SGCA-G.
- Willing and able to give informed consent and follow all study procedures and requirements
Inclusion Criteria - Arm 2:
- Age between 4-65 at enrollment
- Clinically affected (defined as weakness on bedside evaluation in either a limb-girdle pattern, or in a distal extremity)
- a genetically confirmed mutation in SGCA-G
- Willing and able to give informed consent and follow all study procedures and requirements
Exclusion Criteria - Arm 1:
- Any other illness that would interfere with the ability to undergo safe testing or would interfere with interpretation of the results in the opinion of the site investigator.
- History of a bleeding disorder, platelet count <50,000, current use of an anticoagulant.
- Positive pregnancy test at time any timepoint during the trial.
Exclusion Criteria - Arm 2:
- Any other illness that would interfere with the ability to undergo safe testing or would interfere with interpretation of the results in the opinion of the site investigator.
- History of a bleeding disorder, platelet count <50,000, current use of an anticoagulant
- Positive pregnancy test at time any timepoint during the trial.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
---|
CAPN3 (LGMD2A)
Clinical Assessments, Biomarkers
|
DYSF (LGMD2B)
Clinical Assessments, Biomarkers
|
ANO5 (LGMD2L)
Clinical Assessments, Biomarkers
|
DNAJB6 (LGMD1D)
Clinical Assessments, Biomarkers
|
Sarcoglycan (LGMD2D) (LGMD2E) (LGMD2C) (LGMD2F)
Clinical assessments
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in mobility
Time Frame: Baseline to 12 months
|
Mobility will be measured using the 100 Meter Timed Test (100m) in which the participant is asked to complete 2 laps around 2 cones set 25 meters apart as quickly as safely possible, running if able, and the time in seconds is recorded.
|
Baseline to 12 months
|
Change in motor performance
Time Frame: Baseline to 12 months
|
The North Star Assessment for Dysferlinopathy (NSAD) is a functional scale specifically designed to measure motor performance in individuals with LGMD.
It consists of 29 items that are considered clinically relevant items from the North Star Ambulatory Assessment and the Motor Function Measure 20 with a maximum score of 54 and higher scores indicate higher functional abilities.
|
Baseline to 12 months
|
Change in upper limb function characteristics
Time Frame: Baseline to 12 months
|
The Performance of Upper Limb 2.0 (PUL) scale measures the progression of weakness and natural history of functional decline in Duchenne muscular dystrophy.
There are 22 scored items; a score of 42 indicates the highest level of independent function and 0 the lowest.
|
Baseline to 12 months
|
Change in workspace volume
Time Frame: Baseline to 12 months
|
Workspace volume (WSV) will be measured using ACTIVE, an interactive video game which will calculate the combination of upper extremity and trunk strength and function in cubic meters.
|
Baseline to 12 months
|
Change in Forced vital capacity (FVC)
Time Frame: Baseline to 12 months
|
Volume of air forcefully exhaled will be measured using Spirometry performed in a sitting position using standardized equipment
|
Baseline to 12 months
|
Changes in Forced expiratory volume (FEV1)
Time Frame: Baseline to 12 months
|
Volume of air forcefully exhaled in one second will be measured using Spirometry performed in a sitting position using standardized equipment
|
Baseline to 12 months
|
Change in activity limitations
Time Frame: Baseline to 12 months
|
ACTIVLIM is a patient-reported measure of activity limitations for individuals with upper and/or lower limb impairments, which measures the ability to perform daily activities.
|
Baseline to 12 months
|
Change in upper extremity disability
Time Frame: Baseline to 12 months
|
The Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH) questionnaire measures levels of disability in an individual's upper extremity.
|
Baseline to 12 months
|
Change in self-reported physical health
Time Frame: Baseline to 12 months
|
PROMIS Physical Health is part of a set of patient-reported measures developed by a National Institute of Health that evaluates general physical health by assessing fatigue, pain intensity, pain interference, physical function, sleep disturbance, dyspnea, gastrointestinal symptoms, itch, pain behavior, pain quality, sexual function, and sleep related impairment.
|
Baseline to 12 months
|
Change in self-reported mental health
Time Frame: Baseline to 12 months
|
PROMIS Mental Health is part of a set of patient-reported measures developed by a National Institute of Health that evaluates general mental health by assessing anxiety, depression, alcohol use, anger, cognitive function, life satisfaction, meaning and purpose, positive affect, psychosocial illness impact, self-efficacy for managing chronic conditions, smoking, and substance use
|
Baseline to 12 months
|
Change in self-reported social health
Time Frame: Baseline to 12 months
|
PROMIS Social Health is part of a set of patient-reported measures developed by a National Institute of Health that evaluates general social health by assessing ability to participate in social roles and activities, companionship, satisfaction with social roles and activities, social isolation, and social support.
|
Baseline to 12 months
|
Change in whole body health
Time Frame: Baseline to 12 months
|
The Quality of Life in Genetic Neuromuscular Disease Questionnaire was developed to measure whole-body health impact in neuromuscular diseases.
|
Baseline to 12 months
|
Change in overall health
Time Frame: Baseline to 12 months
|
Domain Delta Questionnaire is a patient reported measure that assesses overall health over the previous 12 months.
|
Baseline to 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Nicholas Johnson, MD, Virginia Commonwealth University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HM20018721
- GRASP-LGMD (Other Identifier: Virginia Commonwealth University)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscular Dystrophies
-
Assistance Publique - Hôpitaux de ParisRecruitingLimb Girdle Muscular DystrophiesFrance
-
aTyr Pharma, Inc.CompletedLimb-Girdle Muscular Dystrophies | Facioscapulohumeral Muscular DystrophyUnited States, Denmark, France
-
Wake Forest University Health SciencesMuscular Dystrophy AssociationCompletedMuscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED)United States
-
Sarepta Therapeutics, Inc.Active, not recruiting
-
ML Bio Solutions, Inc.Virginia Commonwealth UniversityCompletedMuscular Dystrophies | Limb Girdle Muscular DystrophyUnited States, Denmark
-
Neurogen Brain and Spine InstituteWithdrawn
-
Rigshospitalet, DenmarkRecruitingLimb Girdle Muscular DystrophyDenmark
-
Rigshospitalet, DenmarkFunding: Toyota Foundation; Funding: Hede Nielsen Foundation; Funding: Grosserer... and other collaboratorsActive, not recruiting
-
GenethonActive, not recruitingLGMD2IDenmark, France, United Kingdom
-
Neurogen Brain and Spine InstituteWithdrawn